Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein  by Bisht, Himani et al.
www.elsevier.com/locate/yviroVirology 334 (20Rapid Communication
Neutralizing antibody and protective immunity to SARS coronavirus
infection of mice induced by a soluble recombinant polypeptide
containing an N-terminal segment of the spike glycoprotein
Himani Bishta,1, Anjeanette Robertsb,1, Leatrice Vogelb, Kanta Subbaraob, Bernard Mossa,T
aLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health,
4 Center Drive, Bethesda, MD 20892-0445, USA
bLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-0445, USA
Received 3 January 2005; returned to author for revision 26 January 2005; accepted 31 January 2005Abstract
A secreted, glycosylated polypeptide containing amino acids 14 to 762 of the SARS coronavirus (SARS-CoV) spike protein and a
polyhistidine tag was expressed in recombinant baculovirus-infected insect cells. Mice received the affinity-purified protein with either a
saponin (QS21) or a Ribi (MPL + TDM) adjuvant subcutaneously and were challenged intranasally with SARS-CoV. Both regimens induced
binding and neutralizing antibodies and protection against SARS-CoV intranasal infection. However, the best results were obtained with
QS21 and protein, which provided the highest antibody as well as complete protection of the upper and lower respiratory tract.
Published by Elsevier Inc.
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Identification of the etiologic agent of severe acute
respiratory syndrome (SARS) has made it possible to work
toward the development of vaccines and therapeutics that
could prevent future recurrences of the disease. SARS-
coronavirus (SARS-CoV) has a nearly 30,000 nucleotides
long RNA genome with 11 open reading frames that encode
four major structural proteins consisting of nucleocapsid,
spike (S), membrane, and small envelope protein (Marra et
al., 2003; Rota et al., 2003). The S protein of SARS-CoV is
a 180- to 200-kDa type-I transmembrane glycoprotein that
has 20–27% amino acid identity with the corresponding
protein of other CoVs, but unlike some is not cleaved into
S1 and S2 subunits. The SARS-CoV S protein mediates cell
entry by binding to a cell receptor identified as angiotensin-
converting enzyme 2 (Li et al., 2003). An additional SARS-0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2005.01.042
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1 H.B. and A.R. contributed equally to the study.CoV receptor, CD209L, which also binds S has recently
been identified (Jeffers et al., 2004). S is a target of
neutralizing antibodies (Berry et al., 2004; He et al., 2004;
Sui et al., 2004) making it an important candidate for
vaccine applications. Currently studied vaccine candidates
for which some protection has been demonstrated in animal
models include DNA (Yang et al., 2004), modified vaccinia
virus Ankara (MVA) (Bisht et al., 2004), and parainfluenza
virus type 3 (Bukreyev et al., 2004) vectors that express S.
Although recombinant DNA and expression vectors gen-
erally induce good cell mediated immunity, they frequently
do not induce as a high an antibody response as adjuvanted
proteins. Here, we demonstrate the induction of neutralizing
antibody and protective immunity to SARS-CoV infection
of mice induced by a soluble secreted polypeptide contain-
ing amino acids 14 to 762 of the S protein in combination
with the saponin QS21 or the Ribi adjuvant MPL + TDM
composed of monophosphoryl lipid A and trehalose
dicorynomycolate. Both adjuvant types have been tested
in phase I clinical trials of candidate vaccines against cancer
and infectious diseases.05) 160–165
Fig. 1. Expression and characterization of SARS-CoV nS glycoprotein. (A)
Schematic representation of pMelBacB-based baculovirus transfer vector.
Abbreviations: PPH, polyhedrin promoter; HBM, DNA encoding honeybee
melittin signal sequence; nS, DNA segment encoding amino acids (aa)
14–762 of the SARS-CoV S protein; His6, DNA encoding 6 histidine
residues. (B) Purified nS analyzed by SDS polyacrylamide gel electro-
phoresis and Coomassie Blue staining (lane 1), silver staining (lane 2) and
Western blot analysis with anti-His mAb (lane 3) or anti-SARS CoV S
polyclonal antibody (lane 4). (C) Purified nS protein was (+) or was not
() treated with peptide N-glycosidase F and was analyzed by SDS
polyacrylamide gel electrophoresis and western blotting with anti-His
mAb and anti-SARS-CoV S polyclonal antibody. Molecular masses of
marker proteins in kDa are shown on the left.
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We considered it impractical to isolate the natural
membrane-bound S glycoprotein from SARS-CoV and
instead used a baculovirus/insect cell system to express an
N-terminal fragment of S (nS) as a secreted glycosylated
protein that could be readily purified under native con-
ditions. The N-terminal 762 amino acids of the S protein
was selected on the basis of hydrophilicity and secondary
structure predictions using Kyte and Dolittle and Chou
Fasman algorithms (McVector 7.2) and because it includes
the region corresponding to S1 of other coronaviruses. A
transfer vector was constructed in which the polyhedrin
promoter regulates expression of a protein comprised of
amino acids 14 to 762 of S preceded by the honeybee
melittin signal peptide and followed by six histidines (Fig.
1A). A baculovirus expressing nS was derived by recombi-
nation in insect cells. The yield of secreted and affinity
purified nS was approximately 10 mg/l of culture super-
natant, and a single major band of ~110 kDa was seen by
SDS-polyacrylamide gel electrophoresis after staining with
Coomassie Blue (Fig. 1B, lane 1) or silver nitrate (Fig. 1B,
lane 2). Upon Western blotting, the same 110-kDa band was
recognized by antibodies to the polyhistidine tag and SARS-
CoV S protein (Fig. 1B, lanes 3 and 4). Treatment with
peptide N-glycosidase F reduced the mobility of the protein
to ~85 kDa, demonstrating that the higher than expected
apparent mass was due to N-glycosylation (Fig. 1C).
To analyze immunogenicity, nS protein mixed with
MPL + TDM or QS21 adjuvant was injected subcutaneously
into BALB/c mice on days 0, 28, and 56. Control mice were
immunized with adjuvant and a secreted form of the vaccinia
virus membrane protein L1R that was also produced in the
baculovirus system and purified by affinity chromatography
(Fogg et al., 2004). As an initial evaluation of immuno-
genicity, sera from the mice were tested for antibodies that
recognize S protein expressed on the surface of cells by re-
combinant modified vaccinia virus Ankara (MVA/S) (Bisht
et al., 2004). Because the endoplasmic reticulum acts as a
filter for misfolded proteins, S present on the cell surface is
likely to be correctly folded. Although SARS-CoV-infected
cells could be used for the same purpose, considerably higher
containment levels would be required. Uninfected HeLa
cells or HeLa cells infected with non-recombinant MVA or
MVA/S were fixed and stained with pooled mouse serum
followed by Alexa 594-conjugated-anti-mouse IgG and
analyzed by confocal microscopy. The serum obtained from
mice immunized with nS in QS21 or MPL + TDM adjuvant
stained the surface of cells infected with MVA/S but did not
detectably stain uninfected cells or cells infected with non-
recombinant MVA (Fig. 2). In contrast, serum from control
mice that were immunized with the vaccinia virus L1R
protein stained cells infected with non-recombinant and
MVA/S equally (not shown). These data indicated that the
antibodies produced by nS were able to bind to the
membrane-associated form of full-length S.The relative binding activity of pooled serum from mice
immunized with nS and QS21 or MPL + TDM adjuvant was
analyzed using nS as the capture antigen. Antibody was
detected after the primary inoculation of nS with QS21 and
the reciprocal ELISA titer was boosted to 1:409,600 after two
more inoculations (Fig. 3A). With MPL + TDM adjuvant, the
antibody response to nS was detected only after boosting but
subsequently reached approximately 25% of the level
achieved with QS21. The IgG2a/IgG1 ratio is an indicator
of Th1 help. The specific IgG2a/IgG1 titers from mice
immunized with QS21 and MPL + TDMwere 0.25 and 0.03,
respectively, suggesting a greater Th1 response with the
former adjuvant. A determining effect of adjuvant on helper T
cell responses has been noted (Cribbs et al., 2003; Santos et
Fig. 3. ELISA and neutralizing antibody responses to nS. Groups of 7
BALB/c mice were immunized subcutaneously with 10 Ag of purified nS
and QS21 or MPL + TDM adjuvant at 4-week intervals (arrows) and
challenged intranasally with 105 TCID50 SARS-CoV on day 82 (arrow
head). Control mice were immunized at the same times with purified
soluble vaccinia virus L1R protein. (A) End-point ELISA titers of pooled
sera collected on days indicated were measured using nS as the capture
antigen. The absorbance obtained with serum from mice immunized with
L1R was subtracted. (B) Dilution of serum that completely prevented
cytopathic effects of SARS-CoV in 50% of wells containing Vero cells was
calculated. Assays were performed on pooled serum collected on days 28
and 56 days and on individual mouse serum collected on day 78. Standard
error bars are shown for the latter.
Fig. 2. Binding of antibodies from mice immunized with nS to full-length
membrane-bound S. HeLa cells were uninfected (A–B), infected with non-
recombinant MVA (C–D) or MVA expressing S (E–H) for 18 h. After
fixation, the unpermeabilized cells were stained with pooled sera from mice
immunized three times with nS and MPL + TDM (E–F) or nS and QS21
(A–D, G–H) followed by Alexa 594-conjugated anti-mouse IgG and
viewed by visible (A, C, E, G) or fluorescence (B, D, F, H) light
microscopy.
Rapid Communication162al., 2002). For comparative purposes, we also determined the
IgG2a/IgG1 ratio of serum previously obtained from mice
immunized with MVA/S. Although the overall IgG titers
were lower in mice immunized with MVA/S (Bisht et al.,
2004) than with the nS protein, the IgG2a/IgG1 ratios were
higher with values of 2 and 4 for pooled sera of mice
immunized intranasally and intramuscularly, respectively.
The high titer of nS-binding antibody and its recognition
of full-length membrane-bound S encouraged us to evaluatethe ability of the immune sera to neutralize the infectivity of
SARS-CoV. Significant neutralizing activity was observed
after the second inoculation of nS with either adjuvant (Fig.
3B). However, the mean neutralizing titer of 1:1269
achieved with QS21 was 4.6-fold higher than that obtained
with MPL + TDM. Thus, there was good correspondence
between the relative binding and neutralizing activities of
sera obtained with QS21 and MPL + TDM adjuvants.
Subbarao et al. (2004) demonstrated that SARS-CoV
replicates in the respiratory tract of BALB/C mice and that
replication was reduced following passive administration of
neutralizing antibody. In this model, peak titers were
reached within 1 to 2 days depending on the dose and
clearing occurred by 7 days. Two days after the intranasal
Rapid Communication 163administration of 105 TCID50 of SARS-CoV, 10
8 TCID50 of
virus per g of lung was recovered in control mice immu-
nized with the vaccinia virus L1R protein in either adjuvant
(Fig. 4A). By contrast, there was at least a 106-fold
reduction in viral load in the lungs of mice immunized
with nS regardless of the adjuvant (Fig. 4A). The difference
was highly significant (P = 0.0017) as determined using the
Mann–Whitney non-parametric statistical method. Indeed,
virus was detected in only one mouse out of seven in each of
the test groups.
The virus titers in the nasal turbinates showed a 103-fold
reduction relative to controls when nS was administered
with MPL + TDM adjuvant and N104-fold reduction when
nS was given with QS21 (Fig. 4B). The effect of vaccination
with either adjuvant was highly significant when compared
with controls (P = 0.0017) determined as above. Virus was
detected in the nasal turbinates of 4 of 7 test mice
immunized with nS and the MPL + TDM adjuvant, whereas
the titers were uniformly below detection in the turbinates of
mice immunized with nS and QS21. The better protection
obtained with the QS21 adjuvant was also statistically
significant (P = 0.0250), using the Mann–Whitney non-Fig. 4. Protection against SARS-CoV replication in immunized mice.
Groups of 7 BALB/c mice were immunized and challenged with SARS-
CoV as described in the legend to Fig. 3. Two days after the challenge, the
virus titers (mean log10TCID50 per g tissue with standard error) were
measured in the lower (A) and upper (B) respiratory tract. The dotted line
represents the lower limit of detection corresponding to 1.8 log10TCID50
per g tissue for upper respiratory tract (A) and 1.5 log10TCID50 per g tissue
for lower respiratory tract (B).parametric statistical method corrected for ties, consistent
with the higher binding and neutralizing antibody titers. The
failure of the nS antibody response to be boosted after
challenge (Fig. 3A) was also consistent with the absence of
virus replication.Discussion
A recombinant polypeptide containing amino acids 14 to
762 of the SARS-CoV S protein administered with adjuvant
induced neutralizing antibody and protectively immunized
mice against upper and lower respiratory infections with
SARS-CoV. Although the ability of a protein vaccine to
protectively immunize against SARS-CoV was not previ-
ously reported, recent studies have shown that the protein
segment we used contains the angiotensin-converting
enzyme 2 receptor-binding region (Babcock et al., 2004;
Wong et al., 2004; Xiao et al., 2003) as well as
immunodominant and neutralizing epitopes (He et al.,
2004; Lu et al., 2004; Sui et al., 2004; Zhou et al., 2004).
The protein vaccine induced higher neutralizing antibody
and more complete protection against an intranasal SARS-
CoV challenge than that achieved by inoculation of mice
with live SARS-CoV (Subbarao et al., 2004), MVA
expressing the full-length S (Bisht et al., 2004), or DNA
expressing full-length S or S lacking the transmembrane and
cytoplasmic domains (Yang et al., 2004). The better
protection achieved in this study is correlated with the
higher antibody response. Although nS with either QS21 or
MPL + TDM was effective, the former adjuvant induced
higher binding and neutralizing antibody and better protec-
tion of the upper respiratory tract. Vaccination with QS21
also induced a more balanced helper T-cell response than
MPL + TDM as indicated by the higher IgG2a/IgG1 ratio.
However, we attribute the greater protection with QS21
adjuvant to the higher overall antibody response since
MVA/S induced a considerably higher IgG2a/IgG1 ratio but
was less protective than nS with QS21.
The mouse model of SARS-CoV has been used in
previous vaccine studies and therefore allowed us to compare
those results with the present ones. However, the mouse
model has limitations because of the absence of disease and
the relatively short period of replication (Subbarao et al.,
2004). Clinical illness has been reported in some monkey
studies (Kuiken et al., 2003) but not in others (Bukreyev et
al., 2004;McAuliffe et al., 2004). SARS-CoV has a relatively
long period of replication in ferrets (Martina et al., 2003) and
Weingartl et al. (2004) recently reported that a recombinant
MVA expressing S did not protect ferrets but contributed to
hepatitis following challenge with SARS-CoV. In that study,
neutralizing antibody was produced only transiently follow-
ing immunization and was not detectable at the time of
challenge although it was subsequently boosted. In another
study, ter Meulen et al. (2004) showed that passively
administered antibody reduced the replication of SARS-
Rapid Communication164CoV in the lungs of ferrets. It will be interesting to determine
whether a protein subunit vaccine is capable of high and
sustained antibody in ferrets or other animals that are highly
susceptible to SARS-CoV.Materials and methods
Vector construction
A cDNA encoding amino acids 14 to 762 of the
SARS-CoV (Urbani strain) S protein (GenBank acces-
sion no. AY278741) with 6 histidine residues appended to
the C-terminus was inserted into the BamHI and EcoRI sites
of the baculovirus transfer vector pMelBacB (Invitrogen) so
that the honeybee melittin signal peptide was in frame with
the S protein. The plasmid and linearized Autographa
californica multiple nuclear polyhedrosis virus DNA were
transfected into SF9 and a recombinant baculovirus was
clonally purified following the Bac-N-Blue system protocol
(Invitrogen).
Expression and purification of recombinant nS protein
High Five cells were infected with recombinant baculo-
virus at a multiplicity of infection of 10 for 120 h at the
National Cell Culture Center (Minneapolis, MN) and the
culture medium was frozen and shipped to us. The culture
supernatant was concentrated 5-fold with a Millipore
Labscale transverse flow filter system and was clarified by
centrifugation in a Sorvall H6000A rotor at 3000 rpm for 30
min at 4 8C. The supernatant was dialyzed against
phosphate pH 7.4 buffered saline (PBS) and then incubated
with a 50% (wt/vol) slurry of nickel-nitrilotriacetic acid (Ni-
NTA) agarose (Qiagen) for 3–4 h at 4 8C. The mixture was
loaded into a column that was washed with 10 bed-volumes
of wash buffer (50 mM phosphate pH 8 buffer/300 mM
NaCl/10 mM imidazole/1 mM phenyl methyl sulfonyl
fluoride), 10 bed-volumes of wash buffer containing 25
mM imidazole, 2 bed-volumes of wash buffer containing 40
mM imidazole, and 3 bed-volumes of wash buffer contain-
ing 200 mM imidazole. The pooled 200 mM imidazole
eluate containing nS was dialyzed against PBS and
concentrated using a Millipore Amicon ultra filter. Protein
samples were analyzed on a 4–12% bis-Tris polyacrylamide
gel (Invitrogen) and stained with GelCode Blue stain
reagent (Pierce) and with Silver Stain Plus kit (BioRad).
Where indicated, N-glycosidase F treatment was carried out
as previously described (Bisht et al., 2004).
Immunological assays
Western blotting was carried out as previously described
using anti-His mouse mAb (Qiagen) or anti-SARS-CoV S
rabbit polyclonal antibody (IMG-541, Imgenex, San Diego)
diluted 1:1000 and 1:500 in blocking buffer, respectively.ELISA and confocal microscopy were carried out as
previously described (Bisht et al., 2004).
Immunization protocol and SARS-CoV challenge
Groups of seven female 6-week BALB/c mice were
injected subcutaneously with 10 Ag of nS protein or with an
unrelated vaccinia virus protein L1R on days 0, 28, and 56.
Approximately 4 weeks after the third immunization, mice
were intranasally challenged with 105 TCID50 of SARS-
CoV in 50 Al. Two days later, their lungs and nasal turbi-
nates were removed and SARS-CoV titers were deter-
mined as described (Subbarao et al., 2004). A non-parametric
Mann–Whitney U test was used for statistical analysis.Acknowledgments
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